Valentin Barsan
Direktor/Vorstandsmitglied bei Neuron23, Inc.
Profil
Valentin Barsan is currently a Director at Arsenal Biosciences, Inc. and Neuron23, Inc. He holds a doctorate degree from Baylor College of Medicine.
Aktive Positionen von Valentin Barsan
| Unternehmen | Position | Beginn |
|---|---|---|
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Direktor/Vorstandsmitglied | 30.03.2022 |
Arsenal Biosciences, Inc.
 Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Valentin Barsan
| Baylor College of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Commercial Services |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | Technology Services |
